Boston Scientific (BSX)
(Delayed Data from NYSE)
$81.60 USD
+0.23 (0.28%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $81.64 +0.04 (0.05%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.60 USD
+0.23 (0.28%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $81.64 +0.04 (0.05%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum C VGM
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Should You Hold Labcorp (LH) Stock in Your Portfolio Now?
by Zacks Equity Research
Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.
Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study
by Zacks Equity Research
Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as the primary study sites.
Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now
by Zacks Equity Research
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segments raise optimism. However, macro issues raise concerns.
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have performed compared to their sector so far this year.
Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now
by Zacks Equity Research
Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).
Zacks.com featured highlights ServiceNow, Boston Scientific and Cooper
by Zacks Equity Research
ServiceNow, Boston Scientific and Cooper have been highlighted in this Screen of The Week article.
3 Profitable S&P 500 Stocks With Room to Run: NOW, BSX, COO
by Tirthankar Chakraborty
ServiceNow (NOW), Boston Scientific (BSX) and The Cooper Companies (COO) have been selected as the top picks with a high net income ratio.
GE HealthCare's (GEHC) Tie-Up to Boost Female Pelvic Healthcare
by Zacks Equity Research
GE HealthCare's (GEHC) latest collaboration is likely to equip clinicians with a toolset to deliver enhanced care to female patients and improve the patient experience.
Boston Scientific (BSX), Silk Road Merger Delayed for Review
by Zacks Equity Research
Boston Scientific (BSX) withdraws its premerger notification and report form to give the U.S. FTC more time to review the proposed acquisition of Silk Road Medical.
Alcon's (ALC) Market Share Gains, New Launches Aid Growth
by Zacks Equity Research
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.
Should You Hold Hologic (HOLX) Stock in Your Portfolio Now?
by Zacks Equity Research
Hologic's (HOLX) strength in molecular diagnostics and the enriched Breast Health business are encouraging.
Walgreens (WBA) Partners With BARDA to Boost Clinical Research
by Zacks Equity Research
Walgreens (WBA) and BARDA form a strategic partnership to bolster the decentralized clinical trial model.
Compelling Reasons to Hold Molina Healthcare (MOH) Stock Now
by Zacks Equity Research
Molina Healthcare (MOH) remains well-poised for growth, attributable to membership growth in Medicaid and Medicare businesses. Buyouts and an adequate cash balance remain other benefits.
Should You Buy, Sell or Hold Medtronic (MDT) Before Q1 Earnings?
by Urmimala Biswas
Medtronic's (MDT) first-quarter profits might have been dented by higher costs and expenses originating from macro issues and geopolitical complexities. However, innovations may have boosted the top line.
Avantor (AVTR) Inks Deal to Optimize Portfolio, Reduce Debt
by Zacks Equity Research
Avantor's (AVTR) latest agreement is likely to enhance its focus on strategic growth opportunities and reduce its debt burden.
Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels
by Zacks Equity Research
Quest Diagnostics (DGX) introduces 13 blood tests to identify micronutrient deficiencies.
The Zacks Analyst Blog Highlights Amazon, Boston Scientific, Shopify and Cooper-Standard
by Zacks Equity Research
Amazon, Boston Scientific, Shopify and Cooper-Standard are included in this Analyst Blog.
Top Research Reports for Amazon, Boston Scientific & Shopify
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Boston Scientific Corporation (BSX) and Shopify Inc. (SHOP), as well as a micro-cap stock, Cooper-Standard Holdings Inc. (CPS).
Bruker (BRKR) Rolls Out the First 1.2 GHz NMR System in Asia
by Zacks Equity Research
Bruker (BRKR) installs the 1.2 GHz Avance NMR Spectrometer at KBSI, enabling advanced scientific discoveries.
Should You Hold Edward Lifesciences (EW) in Your Portfolio Now?
by Zacks Equity Research
Edward Lifesciences' (EW) promising TAVR business and the Critical Care divestment move bode well in the long term.
Here's Why Investors Should Hold Acadia (ACHC) Stock for Now
by Zacks Equity Research
Acadia Healthcare (ACHC) remains well-poised for growth on the back of the solid demand for behavioral healthcare services, continuous pursuit of expansion initiatives and a notable financial position.
Why You Should Add Exact Sciences (EXAS) to Your Portfolio
by Zacks Equity Research
Exact Sciences' (EXAS) progress with strategic priority and strong solvency bode well.
Should Quest Diagnostics (DGX) be in Your Portfolio Now?
by Zacks Equity Research
Quest Diagnostics' (DGX) robust base business performance instills optimism for long-term growth.
Thermo Fisher's (TMO) CDx Gets FDA's Nod for Synovial Sarcoma
by Zacks Equity Research
Thermo Fisher's (TMO) SeCore HLA Typing Kit gets FDA's 510(k) clearance for use as CDx with a TCR Therapy for synovial sarcoma
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.